Skip to main content
Premium Trial:

Request an Annual Quote

Steven Ruben, Martin Latterich, John Varian


Steven Ruben has been appointed vice president for protein therapeutics at Celera Genomics. He will lead target discovery programs for therapeutic antibodies and oversee the company’s cell biology, protein chemistry, and mass spectrometry efforts. He joins Celera from Human Genome Sciences, where he was vice president for research.


Martin Latterich has left his post as director of proteomics at Illumina, to become an associate professor at the Faculty of Medicine of McGill University in Montreal in July. Meanwhile, he is an adjunct assistant professor at the Salk Institute for Biological Studies in La Jolla, Calif. Latterich holds a PhD in molecular cell biology from the University of Durham, UK.


John Varian will become CFO of Deltagen as soon as the company closes a preferred stock private placement it announced in early April. Until then, he will serve as interim CFO. Varian was CFO of Genset from 2000 to 2002. From 1998 to 2000, he was senior vice president for finance and administration at Elan Pharmaceuticals, and before that, CFO at Neurex, which Elan acquired in 1998. He was also previously CFO of Anergen. Varian holds a BBA from Western Michigan University.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.